CAR T-cell therapy for non-Hodgkin lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a type of immunotherapy called CAR T-cell therapy for people with certain types of non-Hodgkin lymphoma that have not responded to other treatments. The goal is to see if this therapy can help control the cancer, and the study will monitor side effects and how well the treatment works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of a type of non-Hodgkin lymphoma, such as diffuse large B-cell lymphoma, follicular lymphoma, or mantle cell lymphoma.
- You must be eligible to receive a standard treatment called CAR T-cell therapy.
- You must have adequate organ function, including bone marrow, kidney, and liver function.
- If you have HIV, it must be well-controlled, with a certain CD4 count and undetectable viral load.
- If you have hepatitis B or C, it must be controlled or treated, with undetectable viral load.
- You must not have active lymphoma in the brain or spinal cord.
- You must not have other active cancers, except for certain low-risk types that are considered cured or stable.
- You must be able to temporarily stop taking blood-thinning medications during the treatment period.
- You must agree to use effective contraception during the study and for a period after treatment if you can become pregnant or father a child.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of CAR T-cell therapy that targets two proteins (CD79b and CD19) on lymphoma cells. It's for people with certain types of non-Hodgkin lymphoma that have come back or not responded to previous treatments.
This trial tests an experimental CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, modified to find and attack cancer cells.
This study tests a new type of CAR T cell therapy that targets the CD20 protein on B-cell lymphoma cells. It is for people with certain types of B-cell lymphoma that have not responded to at least two previous treatments and who cannot use or have already tried the approved CD19 CAR T therapy.
This trial tests a new type of CAR T-cell therapy that targets two proteins (CD20 and CD19) on your cancer cells. It is for people with certain types of lymphoma that have not responded to or have come back after at least two prior treatments.
This trial tests a personalized treatment using your own immune cells (called CAR-T cells) that are modified in a lab to target and kill lymphoma cells. It is for people with a type of B-cell non-Hodgkin lymphoma that has come back or not improved after standard treatments.
This trial studies a type of lab-made immune cell therapy (CAR T) using cells called CAR-20/19-T. It is for adults with relapsed or refractory B-cell cancers, aiming to reduce or eliminate lymphoma in people whose disease has come back or not responded to standard treatments.
Hear when a new Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.